Treating alzheimer’s symptoms can lower cost to health system

Alzheimer’s disease and other dementias will cost the United States $236 billion this year, according to the Alzheimer’s Association. But research being presented this week at the

Alzheimer’s Association International Conference (AAIC) in Toronto suggests costs could be trimmed if patients were more closely monitored by physicians and caregivers. “Today, Alzheimer’s

is incurable and progressive, and some assume that treating dementia is an unjustified cost drain on our health-care system, but this study presents compelling arguments for prescribing the

standard of care,” Maria Carrillo, chief science officer of the Alzheimer’s Association, said in a press release about a new comparison of treated versus untreated patients. The study found

that patients who received medications to alleviate some of the symptoms of Alzheimer’s incurred lower total health care costs and had a lower risk of dying, although that probably was not

because of the drugs but because they more likely had doctors and caregivers paying attention to their health, researchers said. Researchers from Merck, the pharmaceutical company, looked at

the impact of treating newly diagnosed Alzheimer’s patients with one of four available medications. (Merck does not market any of the treatments but is testing the effectiveness of an

experimental Alzheimer’s medication called Verubecestat.) They identified a total of 6,553 Medicare beneficiaries who had just been diagnosed with Alzheimer’s. About 35 percent of them were

treated with one of the four drugs, on average 34 days after their diagnosis. Two-thirds of those treated received donepezil, the generic name for Aricept, which has been on the U.S. market

the longest of all the Alzheimer’s drugs. Untreated patients tended to be older and sicker with other ailments than the treated patients, the researchers found. For an apples-to-apples

comparison, the scientists matched treated with untreated patients on the basis of demographic factors such as age and health status. The study found that among the 694 impaired patients,

those who were treated were less likely to die and had lower monthly total health care costs than those who were not treated. It’s unlikely the medications themselves deserve much credit,

study coauthor Christopher Black of the Merck Research Laboratories told AARP.